Aviragen Therapeutics Inc Share Price Nasdaq
Equities
US0906941002
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
07-08 | HilleVax to discontinue development of norovirus vaccine for infants; shares plummet | RE |
06-14 | Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday | MT |
Sales 2024 * | 24.99M 1.93B | Sales 2025 * | 31.77M 2.45B | Capitalization | 154M 11.84B |
---|---|---|---|---|---|
Net income 2024 * | -98M -7.56B | Net income 2025 * | -112M -8.64B | EV / Sales 2024 * | 6.14 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.83 x |
P/E ratio 2024 * |
-1.22
x | P/E ratio 2025 * |
-1.36
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.55% |
Latest transcript on Aviragen Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Sean Tucker
FOU | Founder | 56 | 31/12/03 |
Phillip Eric Lee
DFI | Director of Finance/CFO | 37 | 18/12/22 |
Michael Finney
CHM | Chairman | 65 | 30/06/07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Yedid
BRD | Director/Board Member | 66 | 24/10/19 |
Elaine Heron
BRD | Director/Board Member | 76 | 24/08/22 |
Michael Finney
CHM | Chairman | 65 | 30/06/07 |
1st Jan change | Capi. | |
---|---|---|
+20.63% | 126B | |
+24.16% | 27.95B | |
-20.17% | 20.5B | |
-16.06% | 17.12B | |
-18.07% | 16.1B | |
-47.70% | 14.97B | |
+11.92% | 14.84B | |
+58.32% | 14.38B | |
+149.98% | 12.37B |